<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article254</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/SUSTAIN" style="display:block; margin-bottom:10px;">SUSTAIN Original</a></li>
<h2><strong>SUSTAIN</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Crizanlizumab in Sickle Cell Disease". The New England Journal of Medicine. 2016.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does crizanlizumab, an antibody against P-selectin, reduce the rate of sickle cell–related pain crises in patients with sickle cell disease?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Crizanlizumab significantly decreased the frequency of sickle cell–related pain crises compared to placebo and showed a low rate of adverse effects in patients with sickle cell disease.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last update, there is no specific mention of crizanlizumab in current guidelines for the treatment of sickle cell disease.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, randomized, placebo-controlled, phase 2 trial.<br/>
N=198 patients with sickle cell disease.<br/>
Intervention groups: low-dose crizanlizumab (2.5 mg/kg), high-dose crizanlizumab (5.0 mg/kg), vs. placebo.<br/>
52 weeks of intravenous treatment followed by a 6-week follow-up.<br/>
Primary outcome: Sickle cell–related pain crises rate.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: Patients 16-65 years old with sickle cell disease experiencing 2-10 pain crises in the previous 12 months.<br/>
Exclusion Criteria: Long-term red-cell transfusion therapy.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
High-dose crizanlizumab (5.0 mg/kg), low-dose crizanlizumab (2.5 mg/kg), or placebo given intravenously.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes: Annual rate of pain crises was 1.63 with high-dose crizanlizumab vs. 2.98 with placebo (45.3% lower rate with high-dose, P=0.01).<br/>
Secondary Outcomes:<br/>
- Median time to first crisis: 4.07 months with high-dose vs. 1.38 months with placebo (P=0.001).<br/>
- Median time to second crisis: 10.32 months with high-dose vs. 5.09 months with placebo (P=0.02).<br/>
- A nonsignificant reduction in the median rate of days hospitalized (P=0.45).<br/>
- A 62.9% lower rate in annual uncomplicated crises (P=0.02).<br/>
- No significant effect on the acute chest syndrome.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Long-term safety and immunogenicity require further monitoring.<br/>
- No significant changes were observed in markers of hemolysis.<br/>
- The impact on patients with genotypes other than HbSS needs further investigation.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by Selexys Pharmaceuticals, NIH, and FDA. Authors disclosed financial relationships with Selexys and other pharmaceutical companies.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
